In an amicus brief submitted to the Supreme Court, AAM urged the Court to uphold the constitutionality of the Inter Partes Review (IPR) process established at the U.S. Patent and Trade Office under the America Invents Act of 2011. AAM explained the important role that the IPR process plays in weeding out invalid patents in an efficient manner, thereby allowing generic and biosimilar competition to start earlier and speeding lower cost alternatives to patients.
